Skip to main content
Springer logoLink to Springer
. 2020 Dec 9;36(4):1033. doi: 10.1007/s00467-020-04874-z

Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Kazuki Tanaka 1,, Brigitte Adams 2, Alvaro Madrid Aris 3, Naoya Fujita 1, Masayo Ogawa 4, Stephan Ortiz 4, Marc Vallee 4, Larry A Greenbaum 5
PMCID: PMC8182874  PMID: 33296010

Correction to: Pediatr Nephrol.

10.1007/s00467-020-04774-2

The published version of the article unfortunately contained a mistake. The baseline FACIT-Fatigue should be 50.0 (42.0–52.0) instead of (42.0–50.0) as it was reported in the original article. The authors apologize for this mistake. The below paragraph was corrected in the original article to reflect the correct values.

“The FACIT-Fatigue scores remained stable throughout the initial evaluation period and extension period up to 1 year (Supplementary Fig.3). The median (range) FACIT-Fatigue value at baseline was 50.0 (42.0, 52.0). The median change from baseline was 0.0 (−5.0, 3.0) at 26 weeks and −1.0 (−7.0, 2.0) at 1 year.”

Footnotes

The online version of the original article can be found at 10.1007/s00467-020-04774-2

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Pediatric Nephrology (Berlin, Germany) are provided here courtesy of Springer

RESOURCES